Related references
Note: Only part of the references are listed.Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
LE Jauregui et al.
CLINICAL INFECTIOUS DISEASES (2005)
Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide
M Buckwalter et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
MB Dorr et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Pharmacokinetics and excretion of dalbavancin in the rat
M Cavaleri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens
I Raad et al.
CLINICAL INFECTIOUS DISEASES (2005)
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide
G Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers
A Leighton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates
JM Streit et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
The use and therapeutic drug monitoring of teicoplanin in the UK
ESR Darley et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections
E Seltzer et al.
CLINICAL INFECTIOUS DISEASES (2003)
Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose
F Pea et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Clinical pharmacokinetics of teicoplanin
APR Wilson
CLINICAL PHARMACOKINETICS (2000)
Share Paper
